Notch-EGFR/HER2 bidirectional crosstalk in breast cancer

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Baker, Andrew ^a   Zlobin, Andrei ^b   Osipo, Clodia ^a,b,c  

^a LUMC   (United States)

^b Oncology Institute   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; Crosstalk; EGFR. HER2; Notch

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL] AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; CAMPTOTHECIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; NOTCH1 RECEPTOR; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CELL COMMUNICATION; CELL PROLIFERATION; GENE OVEREXPRESSION; HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84915798731     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00360     Document Type: Review

References (118)

1. American Cancer Society, Breast Cancer Facts & Figures 2013-2014. 2013.
2. Perou, C.M. Surlie T, Eisen M, Van de Rijn M, Rees C, Pollack J, et al. Molecular portraits of human breast tumours. Nature, 2000. 406(17):747-752.
3. Hu, Z., Fan C., Oh DS., Marron JS, et al., The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006. 7(1): p. 96.
4. Allred, D.C., Ductal Carcinoma In Situ: Terminology, Classification, and Natural History. JNCI Monographs, 2010. 2010(41): p. 134-138.
5. Leonard, G.D. and S.M. Swain, Ductal Carcinoma In Situ, Complexities and Challenges. JNCI Journal of the National Cancer Institute, 2004. 96(12): p. 906-920.
6. Morrow, M., Eric A. Strom, et al. Standard for the Management of Ductal Carcinoma In Situ of the Breast (DCIS). CA Cancer J Clin, 2002. 52: p. 256-276.
7. Burstein, H, Polyak K, Wong J, Susan C. et al. Ductal Carcinoma in Situ of the Breast. N Engl J Med, 2004. 350: p. 1430-1441.
8. U.S. National Library of Medicine, Genetics Home Reference: your guide to understanding genetic conditions2011 July 28, 2014; Available from: http://ghr.nlm.nih.gov/gene/ERBB2http://ghr.nlm.nih.gov/gene/ERBB2.
9. Yarden, Y. Sliwkowski M X, Untangling the ErbB Signalling Network. Nature Reviews, 2001. 2.
10. Bublil, E.M. and Y. Yarden, The EGF receptor family: spearheading a merger of signaling and therapeutics. Current Opinion in Cell Biology, 2007. 19: p. 124-134.
11. Harris, R., EGF receptor ligands. Experimental Cell Research, 2003. 284(1): p. 2-13.
12. Garrett, T., McKern N, Lou M, et al. The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors. Molecular Cell, 2003. 11: p. 495-505.
13. Cho, H.-S., Mason K., Ramyar K. Structure of the extracellularregion of HER2 alone and in complex with the Herceptin Fab. Nature, 2003. 421(6924): p. 753-756.
14. Nahta, R., Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells. Cancer Res, 2005. 65(23): p. 11118-11128.
15. Jones, J.T., Akita R, Sliwkowski M, Binding specificities and affinities of egf domains for ErbB receptors. FEBS Letters, 1999 447: p. 227-231.
16. Tzahar, E. Eldad, Bivalence of EGF-like ligands drives the ErbBsignaling network. The EMBO Journal, 1997. 16(16): p. 4938-4950.
17. Graus-Porta D.,.Beerli R, Daly J, et al., ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal, 1997. 16(7): p. 1647-1655.
18. Rimawi, M.F., Priya S, Heidi W., et al., Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 2010. 116(5): p. 1234-1242.
19. Shigematsu, H. and A.F. Gazdar, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 2006. 118(2): p. 257-262.
20. Gan, H.K., A.H. Kaye, and R.B. Luwor, The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience, 2009. 16(6): p. 748-754.
21. Bronte G, Terrasi M, Rizzo S et al., EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed), 2011. 3: p. 879-887.
22. Dhomen NS, Mariadason J, Tebbutt N et al., Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog, 2012. 17: p. 31-50.
23. Baselga, J., Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology, 2005. 23(11): p. 2445-2459.
24. Yaghoub, S., Masoumeh K., Safar F., et al., Recent advances in head and neck squamous cell carcinoma - A review. Clinical Biochemistry, 2014.
25. Paez, J.G., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004. 304(5676): p. 1497-1500.
26. Sequist, L. and Lynch TJ, EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med, 2008. 59: p. 429-442.
27. Ono, M., Hirata A., and Kometani T, Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther, 2004. 3: p. 465-472.
28. Ross, J.A. and Fletcher, The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells, 1998. 16: p. 413-428.
29. Paik, S. and Liu ET., HER2 as a predictor of therapeutic response in breast cancer. Breast Dis., 2000. 11: p. 91-102.
30. Press, M.F.e.a., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncogene, 1997. 15: p. 2894-2904.
31. Slamon, D., J. Clark G, Wong S, et al, Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 1987. 235(4785): p. 177-182.
32. Casalini, P., L. Botta, and S. Menard, Role of p53 in HER2-induced Proliferation or Apoptosis. Journal of Biological Chemistry, 2001. 276(15): p. 12449-12453.
33. Arteaga, C., Sliwkowski MX, Osborne CK et al., Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol, 2012. 9: p. 16-32.
34. Altomare, D.A. and Testa, Joseph R., Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005. 24(50): p. 7455-7464.
35. Hynes, N.E. and. Lane H.A, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 2005. 5(5): p. 341-354.
36. Sharma, S.V., "Oncogenic Shock": Explaining Oncogene Addiction through Differential Signal Attenuation. Clinical Cancer Research, 2006. 12(14): p. 4392s-4395s.
37. Bray, S.J., Notch signalling: a simple pathway becomes complex. Nature Reviews Molecular Cell Biology, 2006. 7(9): p. 678-689.
38. Carpenter, G., Employment of the Epidermal Growth Factor Receptor in Growth Factor-independent Signaling Pathways. The Journal of Cell Biology, 1999. 146(4): p. 697-702.
39. Ayyanan, A., Civenni, G., Ciarloni, L. et al., Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proceedings of the National Academy of Sciences, 2006. 103(10): p. 3799-3804.
40. Oswald, F., Liptay, S. Adler, G. et al., NF-kB2 Is a Putative Target Gene of Activated Notch-1 via RBP-Jk. Molecular and Cellular Biology, 1998. 18(4): p. 2077-2088.
41. Osipo, C., Golde, T. E. Osborne, B. A. et al., Offthe beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest, 2008. 88(1): p. 11-7.
42. Yamaguchi, N., Oyama, T. Ito, E. et al., NOTCH3 Signaling Pathway Plays Crucial Roles in the Proliferation of ErbB2-Negative Human Breast Cancer Cells. Cancer Res, 2008. 68(6): p. 1881-1888.
43. Osipo, C., Patel, P. Rizzo, P. et al., ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene, 2008. 27(37): p. 5019-5032.
44. Kopan, R. and Ilagan M.X.G., The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell, 2009. 137(2): p. 216-233.
45. Pasinia, A., D. Henriqueb, and D.G. Wilkinsona, The zebrafsh Hairy/Enhancer-of-split-related gene her6 is segmentally expressed during the early development of hindbrain and somites. Mechanisms of Development, 2001. 100: p. 317-321.
46. Palmeirim, I., Henrique D, Ish-Horowicz D., et al., Avian hairy Gene Expression Identifies a Molecular Clock Linked to Vertebrate Segmentation and Somitogenesis. Cell, 1997. 91: p. 639-648.
47. Giudicelli, F. and J. Lewis, The vertebrate segmentation clock. Current Opinion in Genetics & Development, 2004. 14(4): p. 407-414.
48. Lowell, S., Benchoua A, Heavey B, Smith AG, Notch Promotes Neural Lineage Entry by Pluripotent Embryonic Stem Cells. PLoS Biology, 2006. 4(5).
49. Chiba, S., Concise Review: Notch Signaling in Stem Cell Systems. Stem Cells, 2006. 24(11): p. 2437-2447.
50. Artavanis-Tsakonas, S., Notch Signaling: Cell Fate Control and Signal Integration in Development. Science, 1999. 284(5415): p. 770-776.
51. Li, F., Ambrosini G, Chu E, Plescia J, et al, Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998. 396: p. 580-584.
52. O'Connor, D.S., Grossman, D. Plescia, J. et al., Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences, 2000. 97(24): p. 13103-13107.
53. Wall, N.R., O'Connor DS., Plescia J, Janet Plescia Suppression of Survivin Phosphorylation on Thr34 by Flavopiridol Enhances Tumor Cell Apoptosis. Cancer Res, 2003. 63: p. 230-235.
54. Siddiqa, A., Long, L M., Li, L et al., Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 2008. 8(1): p. 129.
55. Lee, C.W., Simin K., Liu Q. et al., A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Research, 2008. 10(6): p. R97.
56. Nickoloff, B.J.,. Osborne B.A, andMiele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene, 2003. 22(42): p. 6598-6608.
57. Reedijk, M., High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival. Cancer Res, 2005. 65(18): p. 8530-8537.
58. Ellisen, L., Bird J, and West DC. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 1991. 66(4): p. 649-661.
59. Fabbri, G., Rasi, S. Rossi, D. et al., Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. Journal of Experimental Medicine, 2011. 208(7): p. 1389-1401.
60. Zagouras, P., Stifani S, Blaumueller CM, et al., Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. USA, 1995. 92: p. 6414-6418.
61. May, R., Riehl T E, Hunt C. et al., Identification of a Novel Putative Gastrointestinal Stem Cell and Adenoma Stem Cell Marker, Doublecortin and CaM Kinase-Like-1, Following Radiation Injury and in Adenomatous Polyposis Coli/Multiple Intestinal Neoplasia Mice. Stem Cells, 2008. 26(3): p. 630-637.
62. Akiyoshi, T., Masafumi N, Kosuke Y et al., y-Secretase Inhibitors En hance Taxane-Induced Mitotic Arrest and Apoptosis in Colon Cancer Cells. Gastroenterology 2008: p. 131-144.
63. Konishi, J., Kawaguchi, K. S. Vo, H. et al., y-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers. Cancer Res, 2007. 67(17): p. 8051-8057.
64. Rose, S.L., Kunnimalaiyaan, M, Drenzek, J., et al., Notch 1 signaling is active in ovarian cancer. Gynecologic Oncology, 2010. 117(1): p. 130-133.
65. Nakayama K., Nakayama N., Jinawath N., et al., Amplicon profiles in ovarian serous carcinomas. International Journal of Cancer, 2007. 120(12): p. 2613-2617.
66. Shimizu K. Chiba S., Saito T., et al., Functional Diversity among Notch1, Notch2, and Notch3 Receptors. Biochemical and Biophysical Research Communications, 2002. 291(4): p. 775-779.
67. Parr C, Watkins G, Jiang WG, The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004. 14: p. 779-786.
68. O'Neill, C.F., Urs, S., Cinelli, C., et al., Notch2 Signaling Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth. The American Journal of Pathology, 2007. 171(3): p. 1023-1036.
69. Dotto, G.P., Notch tumor suppressor function. Oncogene, 2008. 27(38): p. 5115-23.
70. Klinakis, A., Lobry C. Abdel-Wahab O. et al., A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature, 2011. 473(7346): p. 230-3.
71. Clarke, E.E., Churcher, I. Ellis, S. et al., Intra-or Intercomplex Binding to the-Secretase Enzyme: A Model to Differentiate Inhibitor Classes. Journal of Biological Chemistry, 2006. 281(42): p. 31279-31289.
72. Olsauskas-Kuprys, R., Zlobin A., and C. Osipo C., Gamma secretase inhibitors of Notch signaling. OncoTargets and Therapy, 2013. 6: p. 943-955.
73. Zhang C.C., Pavlicek A., Zhang, Q., et al., Biomarker and Pharmacologic Evaluation of the-Secretase Inhibitor PF-03084014 in Breast Cancer Models. Clinical Cancer Research, 2012. 18(18): p. 5008-5019.
74. Kumar, J.P. and Moses K., EGF Receptor and Notch Signaling Act Upstream of Eyeless/Pax6 to Control Eye Specification. Cell, 2001. 104: p. 687-697.
75. Tsuda, L., Raghavendra N S., Zipursky L., et al., An EGFR/Ebi/Sno Pathway Promotes Delta Expression by Inactivating Su(H)/SMRTER Repression during Inductive Notch Signaling. Cell, 2002. 110: p. 625-637.
76. Price, J.V., Savenye D., Lum D., et al., Dominant Enhancers of EGR in Drosophila melanogaster: Genetic Links Between the Notch and EGFR Signaling Pathways. Genetics 1997. 147: p. 1139-1153.
77. Kolev, V., Mandinova A., Guinea-Viniegra J., et al., EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nature Cell Biology, 2008. 10(8): p. 902-911.
78. Purow, B.W., Sundaresan, T. K. Burdick, M. J. et al., Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis, 2008. 29(5): p. 918-925.
79. Xie, M., He, C-S., Wei, S-H, et al., Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. European Journal of Cancer, 2013. 49(16): p. 3559-3572.
80. Kang, J.H., Lee, E. H. Park, S. W. et al., MUC5AC Expression through Bidirectional Communication of Notch and Epidermal Growth Factor Receptor Pathways. The Journal of Immunology, 2011. 187(1): p. 222-229.
81. Esteva, F.J.G., H, Zhang S, Santa-Maria C, et al., PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer. The American Journal of Pathology, 2010. 177: p. 1647-1656.
82. Gallardo A., Lerma E., Escuin D, et a, Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. British Journal of Cancer, 2012. 106: p. 1367-1373.
83. Palomero, T., Lim, W. K. Odom, D. T., et al., Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007. 13(10): p. 1203-1210.
84. Veeraraghavalu K, Subbaiah V., Srivastava S, et al., Complementation of Human Papillomavirus Type 16 E6 and E7 by Jagged1-Specific Notch1-Phosphatidylinositol 3-Kinase Signaling Involves Pleiotropic Oncogenic Functions Independent of CBF1;Su(H);Lag-1 Activation. Journal of Virology, 2005. 79(12): p. 7889-7898.
85. Lu, C.H., Wyszomierski S L., Tseng L. M., et al., Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. Clinical Cancer Research, 2007. 13(19): p. 5883-5888.
86. Eichhorn, P.J.A., Gili, M. Scaltriti, M. et al., Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP BEZ235. Cancer Res, 2008. 68(22): p. 9221-9230.
87. Dong, Y., Li, A. Wang, J. et al., Synthetic Lethality through Combined Notch-Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer. Cancer Res, 2010. 70(13): p. 5465-5474.
88. Meurette O., Stylianou S. Rock R. et al., Notch Activation Induces Akt Signaling via an Autocrine Loop to Prevent Apoptosis in Breast Epithelial Cells. Cancer Research, 2009. 69(12): p. 5015-5022.
89. Mungamuri, S.K., Survival Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)-Dependent Inhibition of p53. Cancer Research, 2006. 66(9): p. 4715-4724.
90. Sergina, N.V., Rausch M., Wang, D., et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 2007. 445(7126): p. 437-441.
91. Bianco, R., Shin I., Ritter CA. et al., Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 2003. 22(18): p. 2812-2822.
92. Engelman, J.A., Kreshnik Z., Tetsuya M., et al., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3, Signaling. Science, 2007. 316(5827): p. 1039-1043.
93. Krol, J., Francis R. E. Albergaria A. et al., The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Molecular Cancer Therapeutics, 2007. 6(12): p. 3169-3179.
94. Han, J., Ma, I., Hendzel MJ. et al., The cytotoxicity of ?-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by ?-secretase inhibition. Breast Cancer Research, 2009. 11(4): p. R57.
95. Ercan, D., Xu, C. Yanagita, M. et al., Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2012. 2(10): p. 934-947.
96. Hasson, P. and Z. Paroush, Crosstalk between the EGFR and other signalling pathways at the level of the global transcriptional corepressor Groucho/TLE. British Journal of Cancer, 2006. 94(6): p. 771-775.
97. Pandya, K., Meeke, K. Clementz, A. G. et al., Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer, 2011. 105(6): p. 796-806.
98. Ju J-h., Yang W., Oh S., et al., HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. Biochemical Journal, 2013. 451(1): p. 123-134.
99. Pradeep, C.R., Köstler, W. J. Lauriola, M., et al., Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene, 2011. 31(7): p. 907-917.
100. Farnie, G., Willan, P M. Clarke, R B. et al., Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status. PLoS ONE, 2013. 8(2): p. e56840.
101. Diaz, B., Yuen A., Iizuka S., et al., Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. The Journal of Cell Biology, 2013. 201(2): p. 279-292.
102. Harrison, H., Simões BM., Rogerson L., et al., Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Research, 2013. 15(2): p. R21.
103. Sooman, L., Ekman S., Andersson C., et al., Synergistic i nteractions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. Cancer Chemotherapy and Pharmacology, 2013. 72(2): p. 329-340.
104. Ma, J.M., Meng Y., Kwiatkowski D., Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. The Journal of Clinical Investigation, 2010. 120: p. 103-114.
105. Chan, S., Weng., A., Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood, 2007. 110: p. 278-286.
106. Calzavara E., Chiaramonte R., Cesana D, Reciprocal Regulation of Notch and PI3K/Akt Signalling in T-ALL Cells In Vitro. Journal of Cellular Biochemistry, 2008. 103: p. 1405-1412.
107. Izrailita, J. Bermana, H. Dattid, A., High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFß pathways as fundamental Notch regulators in breast cancer. PNAS, 2013. 110: p. 1714-1719.
108. Sethi N; Dai X., Winter C., Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells. Cancer Cell, 2011. 19: p. 192-205.
109. Zhang, L., Guo S., and Gonzalez-Perez R.R., Notch, IL-1 and Leptin Crosstalk Outcome (NILCO) Is Critical for Leptin-Induced Proliferation, Migration and VEGF/VEGFR-2 Expression in Breast Cancer. PLoS ONE, 2011. 6(6): p. e21467.
110. Efferson, C.L., Winkelmann C. T., Ware C. et al., Downregulation of Notch Pathway by a-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model. Cancer Research, 2010. 70(6): p. 2476-2484.
111. Narod, S.A. and E. Rakovitch, A comparison of the risks of in-breast recurrence after a diagnosis of DCIS or early invasive breast cancer. Current Oncology, 2014. 21(3): p. 119.
112. Wiechmann, L. and H.M. Kuerer, The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer, 2008. 112(10): p. 2130-2142.
113. Ignatiadis, M. and C. Sotiriou, Luminal breast cancer: from biology to treatment. Nature Reviews Clinical Oncology, 2013. 10(9): p. 494-506.
114. Dawson S-J., Rueda, O M. Aparicio, S., et al., A new genome-driven integrated classification of breast cancer and its implications. The EMBO Journal, 2013. 32(5): p. 617-628.
115. Ades F., Zardavas D. Bozovic-Spasojevic I., et al., Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of Clinical Oncology, 2014. 32(25): p. 2794-2803.
116. Lehmann B.D., Bauer, JA., Chen X., et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 2011. 121(7): p. 2750-2767.
117. Hicks, C., Johnston CH., diSibio G., et al., Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. Nature Cell Biology, 2000. 2.
118. Huang Y.Z., Won S.,. Ali D W., et al., Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses. Neuron, 2000 May. 26: p. 443-455.